Comparison of the efficacy and safety of CELBESTA (R) versus CELEBREX (R) in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyun-Sook | - |
dc.contributor.author | Choi, Won-Ho | - |
dc.contributor.author | Kim, Bo Young | - |
dc.contributor.author | Kim, Sung Soo | - |
dc.contributor.author | Lee, Sang-Il | - |
dc.contributor.author | Kim, Sang-Hyon | - |
dc.contributor.author | Choi, Sung Jae | - |
dc.contributor.author | Kim, Geun-Tae | - |
dc.contributor.author | Hur, Jin-Wuk | - |
dc.contributor.author | Lee, Myeung-Su | - |
dc.contributor.author | Kim, Yun Sung | - |
dc.contributor.author | Hong, Seung-Jae | - |
dc.date.accessioned | 2021-08-30T22:25:40Z | - |
dc.date.available | 2021-08-30T22:25:40Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 0300-0605 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/55545 | - |
dc.description.abstract | Objectives: Celecoxib is a selective cyclooxygenase (COX)-2 inhibitor that is commonly used to reduce the incidence of gastrointestinal (GI) complications in patients with rheumatoid arthritis (RA). CELBESTA (R) is a generic equivalent to CELEBREX (R), a celecoxib preparation. This study compared the efficacy and safety of CELBESTA (R) and CELEBREX in patients with RA. Methods: This was a multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority clinical trial. The primary endpoint was a change from baseline in self-assessed pain intensity determined using a 100-mm visual analog scale after 6 weeks of treatment. Results: After a washout period, 119 eligible subjects were randomized to one of two groups (CELBESTA (R) group, n = 61; CELEBREX (R) group, n = 58). CELBESTA (R) was not inferior to CELEBREX (R) because the upper limit of two-sided 95% confidence interval (CI) for the difference between the two groups (difference in the least square [LS] mean, -8.68 mm; two-sided 95% CI -16.59 mm to -0.77 mm) was less than the non-inferiority margin (10 mm). There were no significant differences in GI complications and renal toxicity. Conclusions: CELBESTA (R) was not inferior to CELEBREX (R) with regard to the pain relief efficacy in RA patients, and the tolerability and safety profiles were excellent and at similar levels for both preparations. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.subject | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | - |
dc.subject | OSTEOARTHRITIS | - |
dc.subject | CELECOXIB | - |
dc.subject | NONINFERIORITY | - |
dc.subject | PAIN | - |
dc.title | Comparison of the efficacy and safety of CELBESTA (R) versus CELEBREX (R) in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Sung Jae | - |
dc.identifier.doi | 10.1177/0300060520931323 | - |
dc.identifier.scopusid | 2-s2.0-85086833599 | - |
dc.identifier.wosid | 000545624500001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, v.48, no.6 | - |
dc.relation.isPartOf | JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | - |
dc.citation.title | JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | - |
dc.citation.volume | 48 | - |
dc.citation.number | 6 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | - |
dc.subject.keywordPlus | OSTEOARTHRITIS | - |
dc.subject.keywordPlus | CELECOXIB | - |
dc.subject.keywordPlus | NONINFERIORITY | - |
dc.subject.keywordPlus | PAIN | - |
dc.subject.keywordAuthor | CELBESTA® | - |
dc.subject.keywordAuthor | CELEBREX® | - |
dc.subject.keywordAuthor | gastrointestinal toxicity | - |
dc.subject.keywordAuthor | Korea | - |
dc.subject.keywordAuthor | non-inferiority | - |
dc.subject.keywordAuthor | pain relief | - |
dc.subject.keywordAuthor | renal toxicity | - |
dc.subject.keywordAuthor | rheumatoid arthritis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.